NeoGenomics Q4 revenue up 11% to $190M; full-year net loss widens to $108M; RaDaR ST MRD launch imminent

NEOGENOMICS INC

Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.
Q4 net loss decreased 36% to $10M; full-year net loss increased 37% to $108M; Adjusted EBITDA positive $13M (Q4) and $43M (FY).
Clinical NGS volumes grew 23% in Q4 and 22% for full year, outpacing market growth.
RaDaR ST MRD assay imminent clinical launch; company addresses $20B+ MRD monitoring market; modest 2026 revenue expected.
Successfully resolved RaDaR ST patent litigation (no financial details disclosed).

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.